Abstract
Recent reports suggest a potentially beneficial increase in abiraterone exposure when abiraterone acetate plus prednisone is administered with food. We evaluated the basis for current dosing recommendations under modified fasted conditions for patients with metastatic castration-resistant prostate cancer with a PubMed search of studies assessing the impact of food on abiraterone pharmacokinetics. Studies show that abiraterone exposure increases with administration in a fed versus fasted state and with high-fat versus low-fat meals. Food effect is substantially attenuated in metastatic castration-resistant prostate cancer patients compared with healthy subjects. The potential variability in absorption, unproven clinical benefits and increased toxicity with abiraterone acetate plus prednisone administration in the fed state underscore the importance of adhering to current dosing recommendations.
Financial & competing interests disclosure
This work was supported by Janssen Research & Development. C Chien, M Smith and P De Porre are employees of Janssen Research & Development and own stock in Johnson & Johnson. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Writing assistance was provided by Shala Thomas, PhD, of PAREXEL, and was funded by Janssen Global Services, LLC.